HomepageONC • NASDAQ
add
BeOne Medicines AG
$Â 244,32
Na sluitingstijd:(0,00%)0,00
$Â 244,32
Gesloten: 2 jul, 16:00:11 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 245,16
Dag-range
$Â 239,25 - $Â 244,65
Jaar-range
$Â 172,67 - $Â 287,88
Beurswaarde
30,72Â mld. USD
Gem. volume
332,91K
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,12Â mld. | 48,64% |
Bedrijfskosten | 941,18Â mln. | 5,98% |
Netto inkomsten | 1,27Â mln. | 100,51% |
Netto winstmarge | 0,11 | 100,33% |
Winst per aandeel | 0,07 | 103,00% |
EBITDA | 42,73Â mln. | 118,01% |
Effectief belastingtarief | 93,92% | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 2,52Â mld. | -9,91% |
Totale activa | 5,84Â mld. | 3,07% |
Totale passiva | 2,34Â mld. | 1,50% |
Totaal aandelenvermogen | 3,50 mld. | — |
Uitstaande aandelen | 107,95 mln. | — |
Koers-boekwaardeverhouding | 7,56 | — |
Rendement op activa | 0,47% | — |
Rendement op kapitaal | 0,62% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 1,27Â mln. | 100,51% |
Operationele kasstroom | 44,08Â mln. | 114,29% |
Kasstroom uit beleggingen | -121,94Â mln. | 41,89% |
Kasstroom uit financiering | -33,78Â mln. | -120,81% |
Nettomutatie in liquide middelen | -108,16Â mln. | 71,43% |
Vrije kasstroom | -145,31Â mln. | 62,90% |
Over
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Opgericht
28 okt 2010
Website
Werknemers
11.000
